Ergocalciferol

Hypoparathyroidism, refractory/vitamin D resistant rickets and familial hypophosphatemia.

Nutritional-deficiency repletion is outside this capsule’s listed indications. The 2024 prevention guideline addresses people without established indications; it does not supply a universal high-dose deficiency course. Current adult hypoparathyroidism guidance prefers activated vitamin D when available.

The 2025 ESE guideline prefers activated vitamin D analogues. Supraphysiological calciferol is reserved for special circumstances or lack of access and carries toxicity risk; vitamin D3 is preferred in that fallback. Native D2/D3 800–2,000 IU/day supports vitamin D status in adult hypoparathyroidism, separate from activated-drug treatment.

Do not turn broad label ranges into capsule-count instructions. Verify the prescribed frequency, total supplements and calcium plan; adjust with response. The label supplies no renal/hepatic dose algorithm. Renal disease, phosphate elevation and impaired metabolite activation require specialist assessment to prevent calcification.

Hypercalcemia, malabsorption syndrome, abnormal sensitivity to vitamin D toxic effects, or hypervitaminosis D, as specified by the selected label.

The selected U.S. label has no boxed warning. Its high-dose toxicity precautions remain essential.

Toxicity may cause nausea, appetite loss, constipation, weakness, excessive thirst/urination, hypercalciuria, renal failure and widespread calcification; child growth and adult bone mineralization can be harmed. Effects may persist ≥2 months after stopping. Suspected overdose requires urgent assessment, stopping further vitamin D and clinician-directed calcium/renal management.

• Mineral oil impairs fat-soluble vitamin absorption.
• Thiazides can cause hypercalcemia in hypoparathyroid patients treated with ergocalciferol; monitor the calcium plan.
• Review other vitamin D sources and calcium intake before increasing treatment; avoid unplanned duplicate products.

The capsule label warns about hypervitaminosis D fetal harm and retains legacy “above 400 IU” safety wording; this is not a modern universal intake ceiling. The 2024 guideline suggests empiric supplementation in healthy pregnancy, within its separate scope. High-dose rare-disorder therapy requires specialist review. Large maternal doses can cause infant hypercalcemia; assess infant calcium as directed.

Pediatric doses must be individualized; the 50,000 IU capsule is not a routine infant product. Older-adult studies are limited; cautious selection reflects organ function, comorbidity and other medicines.

Activated metabolites promote intestinal calcium/phosphate absorption and affect bone/renal mineral handling. Ergocalciferol is vitamin D2, not cholecalciferol (D3) or calcitriol.

Activation

Liver forms 25-hydroxyvitamin D; kidney forms active 1,25-dihydroxyvitamin D.

Label onset lag

Approximately 10–24 hours before action begins.

Persistence

Excess-dose effects may persist for two or more months.

Dose conversion

1 microgram D2 = 40 IU; 50,000 IU = 1,250 micrograms.

• Label high-dose regimens: calcium/phosphorus every 2 weeks or more often; monthly bone radiographs until correction/stability.
• Adult hypoparathyroidism guideline: calcium, phosphate, magnesium, creatinine/eGFR and symptoms; reassess soon after treatment changes and evaluate urinary calcium/renal complications as appropriate.
• Review all vitamin D/calcium intake, toxicity symptoms and adherence to exact frequency.

Check units and daily versus weekly or other schedule at every refill. Do not add vitamin D/calcium supplements independently. Report nausea, constipation, marked thirst, frequent urination, weakness or confusion. Keep capsules away from children; tell clinicians about pregnancy, breastfeeding and new medicines.

Strength

1.25 mg = 1,250 micrograms = 50,000 IU D2.

Appearance / imprint

Clear forest-green oval softgel; E09.

Distributor / manufacturer

Torrent Pharma / Esjay Pharma.

Example NDC

13668-757-01 · 100 capsules.

U.S. status

Prescription capsule.

Selected product

50,000 IU oral softgel capsule.

Outside scope

Other D2 liquids/supplements, D3 products and activated analogues; no automatic substitution.

Store at 25°C, excursions 15–30°C; protect from light. Dispense in a tight, light-resistant container. Check exact ingredients for tartrazine/soy/gelatin concerns.